Alto Pharmacy vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Alto Pharmacy is a full-service digital pharmacy delivering prescriptions to patients with a tech-enabled experience that coordinates with providers and insurance.
About
Alto Pharmacy is a digital pharmacy company founded in 2015 that provides a tech-enabled prescription delivery experience for patients managing ongoing medications and specialty drugs. The company differentiates from traditional pharmacies through proactive care coordination, where pharmacy staff work with patients and prescribers to address insurance prior authorizations, copay assistance programs, and adherence support rather than requiring patients to navigate these barriers themselves. Alto serves both retail pharmacy customers and specialty pharmacy customers managing complex medications for conditions including fertility, oncology, HIV, and mental health. The company raised over $350M and delivers to patients in multiple major US metropolitan areas. Alto's platform integrates with electronic health record systems to receive prescriptions digitally and provides prescribers with real-time visibility into whether patients have filled their medications. The company has positioned its proactive, high-touch model as particularly valuable for specialty drugs where adherence, insurance navigation, and side effect management require more support than standard retail pharmacies provide. Alto Pharmacy serves as an alternative to incumbent pharmacy benefit managers for employers and health plans that want better specialty pharmacy management.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.